August 14, 2017 09:52 AM EDT

In a rare misfire, Regeneron scraps its RSV drug after a PhIII failure

John Carroll

Editor & Founder

In a rare Phase III failure, Regeneron says its late-stage antibody for RSV — suptavumab (REGN2222) — flopped in a major study which enrolled more than a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In a rare misfire, Regeneron scraps its RSV drug after a PhIII failure

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Merck pays $30M to buy ‘chameleon’ approach to deadly brain cancers

Eye drop maker to merge with a retinal gene therapy startup from Spark co-founder

UK’s price watchdog says Lilly’s Alzheimer’s drug is too costly for broad uptake

Corrected: Sangamo to seek accelerated approval for Fabry gene therapy, claims it won't need confirmatory study

Amgen preps to launch Eylea biosimilar years early after Regeneron loses appeal

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

In a rare mis­fire, Re­gen­eron scraps its RSV drug af­ter a PhI­II fail­ure

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

In a rare misfire, Regeneron scraps its RSV drug after a PhIII failure